Given that several of the non-selective RTKIs exhibit inhibitory activities against both FGFR and VEGFR pathways (e.g., pazatinib, dovitinib, and regorafenib), their “off-target” effects increasing chemosensitivity of cancers were discussed above in the corresponding chapter. The gene discussed is KDR; the disease is cancer.